about
ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study.Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas.Evaluating a newly developed pharmacogenetic array: screening in a Spanish population.Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos.Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.Reduced completed suicide rate in Hungary from 1990 to 2001: relation to suicide methods.QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios.Reproducibility over time of the urinary diclofenac/4'-OH diclofenac ratio among different CYP2C9 genotypes.CYP2C9 gene and susceptibility to major depressive disorder.Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers.Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis.CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.CYP2D6 polymorphism and mental and personality disorders in suicide attempters.CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards.Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico.Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms.Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem.
P50
Q33928098-422095FC-DF5A-4B1D-B270-77F861736454Q34909452-C5BE248B-B707-48E2-8DC4-1D86D377B5D6Q36683874-D51A2D0E-897C-40B4-BD5A-5C95F7933561Q36725206-42FAF66A-9B67-4B5F-8AE0-0F139DFAE4E4Q36747019-5FFC5B43-F713-4D94-8F97-A5FA5ED3EA92Q37012022-A92A7BE9-A84F-4F65-9658-A673FF9762ADQ38803195-378787C1-DA2F-4A16-AA47-C5D90E216BDAQ41631036-707D96D2-FDA7-48BD-A5AD-35498EB3CBD4Q41704650-04C9FA2E-395D-4BB2-9499-04E059C50E47Q42788951-91F09628-6643-475D-B413-137E02142DD7Q43001385-79DBF12C-DB47-4DC1-A7EF-56ABD2BB1FFBQ43860978-323F5D55-CF2A-4FD9-B14F-ABAA4957254EQ43874208-66DF6E92-BC38-408E-9A7D-FFC7E0EB99F5Q44089505-216A9A82-0C8D-4F8B-A187-A6EF42DB51A0Q44228212-37A31074-9A19-47FC-A745-3D5AD635EEA3Q44228265-F8B9429A-7941-4269-9A06-A6C23AC8EFB0Q44246154-B8AE90FE-1B47-4335-BC05-4CC9FF64A4C7Q44263549-8149ED8B-E51F-4A83-8735-FDAB587E40ADQ44272336-B9FD7B5A-F393-42D2-8E44-FB0308B53BCEQ44395024-D677CC0F-101F-438A-904A-7AFC37AEA840Q44432237-5EF1CA36-C045-423D-995D-B4F758F7B946Q44437706-D1758CB4-08C0-4618-97AD-A5C947BD31C3Q44607096-569E0C92-1734-4BC4-9E80-48B9D183D7D6Q44635668-7875D9BE-510F-43A9-B1F9-FD15FF178C35Q44730960-1AFDCC09-1148-4CE6-8396-D0D933EF2B05Q44761323-28BCDB9E-2569-4396-8A95-00F93CAE4B78Q44817337-56EB292E-F1EF-46C5-AC9B-E02255BD7FB0Q44983984-693B08E2-42C1-4852-AEE3-C232BE6BFD58Q45292606-A00FF067-4262-4E0F-BB06-714EF1D0672AQ45418747-5F33B3C2-C4C5-44E7-AABB-7CDE5B0ABEA5Q45886052-0F0206CE-65CE-42DA-B267-6496281FF00FQ45928694-772795C7-E637-45D5-B443-8DC922F5E5DBQ46137709-DD612EA3-D6E9-4FAF-9DE7-19CC60DDE363Q46221248-E0AAE23F-04B8-4D93-8B64-C45C6A83890EQ46298744-33979A18-9402-4193-A857-EA4C3E44E178Q46447863-2DE12DA3-21E3-48E2-A8F2-E756470F773FQ46504854-2E2F17AB-78A2-41E9-88B9-E53F4924EA9DQ46544571-A2DD5BA6-E64C-40AF-87B8-CD62DA57AFE6Q46595334-32D8CC02-3926-4560-9BFC-456D40978D8FQ46733598-6C6AC876-FD42-4910-8823-8DFEB137647F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pedro Dorado
@ast
Pedro Dorado
@en
Pedro Dorado
@es
Pedro Dorado
@nl
Pedro Dorado
@sl
type
label
Pedro Dorado
@ast
Pedro Dorado
@en
Pedro Dorado
@es
Pedro Dorado
@nl
Pedro Dorado
@sl
prefLabel
Pedro Dorado
@ast
Pedro Dorado
@en
Pedro Dorado
@es
Pedro Dorado
@nl
Pedro Dorado
@sl
P1053
A-3917-2011
P106
P1153
6602105006
P21
P31
P3829
P496
0000-0003-4100-721X